
Bluejay Diagnostics, Inc.
77
Recent developments highlight Bluejay Diagnostics' clinical progress, financial strengthening, strategic partnerships, and corporate actions such as reverse stock splits.
- Bluejay Diagnostics announced a 1-for-4 reverse stock split in November 2026 [N1].
- The company completed enrollment in its SYMON-II sepsis study as of July 2026 [N7].
- Bluejay reported Q2 2026 results showing a strengthened cash position ahead of its planned Symphony IL-6 FDA filing [N5].
- Bluejay Diagnostics formed a partnership with Lovell to access the U.S. federal healthcare market [N4].
- The company’s common stock price was $2.80 as of November 11, 2026, maintaining compliance with Nasdaq’s minimum bid price requirement [S2].
- Bluejay Diagnostics announced a private placement of up to $23.6 million in June 2026 [N12].
Bluejay Diagnostics, Inc. is a clinical-stage diagnostics company focused on developing innovative diagnostic tests for inflammatory and infectious diseases. The company is advancing its SYMON-II sepsis study and preparing to submit a 510(k) regulatory application to the FDA for its Symphony IL-6 diagnostic. Bluejay has strengthened its cash position through private placements and strategic partnerships, including collaborations to access the U.S. federal healthcare market. The company is listed on the Nasdaq Capital Market and has implemented reverse stock splits to maintain listing standards.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Bluejay Diagnostics, Inc. is actively engaged in clinical development of diagnostic products, including the SYMON-II sepsis study and preparation for FDA 510(k) submission for its Symphony IL-6 diagnostic. The company reported cash and cash equivalents of approximately $7.4 million and a net loss of about $2.0 million for the nine months ended September 30, 2026. Bluejay has undertaken reverse stock splits and strategic partnerships to support its business and maintain Nasdaq listing compliance. The company faces risks related to capital requirements and liquidity but maintains strong short-term liquidity ratios as of September 2026.
Bluejay Diagnostics has demonstrated progress in clinical development with the completion of enrollment in its SYMON-II sepsis study and plans for FDA 510(k) submission for its Symphony IL-6 diagnostic. Strengthened cash reserves and strategic partnerships support operational continuity and potential market expansion. Successful regulatory approval and commercialization could enhance the company's position in the diagnostics market.
The company has incurred significant net losses and an accumulated deficit, reflecting ongoing development costs without current operating income. Bluejay faces capital raising risks that could impact its ability to continue operations. Multiple reverse stock splits indicate challenges in maintaining Nasdaq listing compliance. Failure to secure additional financing or regulatory approvals could adversely affect business continuity and shareholder value.
Bluejay Diagnostics operates in the specialized diagnostics sector with a focus on inflammatory and infectious disease markers, such as IL-6 for sepsis. Its moat is derived from proprietary diagnostic technologies and ongoing clinical validation efforts, which may provide competitive differentiation if regulatory approvals are obtained. Strategic partnerships enhance market access potential. However, as a clinical-stage company, its moat is contingent on successful regulatory and commercial execution.
• Capital and Liquidity Risk: Bluejay Diagnostics requires additional capital to fund its business plan and regulatory submissions. Failure to raise sufficient funds could lead to liquidation under U.S. bankruptcy laws [S2].
• Regulatory Approval Risk: The company’s business depends on obtaining FDA clearance for its diagnostic products. Delays or failure in regulatory approval could impede commercialization efforts.
• Market Listing Risk: The company must maintain minimum bid price and market capitalization requirements to remain listed on Nasdaq. Failure to meet these could result in delisting and reduced liquidity [S2].
• Operational Risk: As a clinical-stage company, Bluejay faces risks related to clinical trial outcomes, product development, and commercialization execution.
Business trends: Continued clinical development of diagnostic products, including sepsis diagnostics, and strategic partnerships to expand market access.
Execution milestones: Completion of FDA 510(k) submission for Symphony IL-6 diagnostic and potential regulatory approvals.
Key risks: Capital raising challenges, regulatory approval uncertainties, and Nasdaq listing compliance risks.
High visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Bluejay Diagnostics, Inc. is a company engaged in developing diagnostic products, including those related to sepsis and inflammatory conditions.
- The company completed enrollment in its SYMON-II sepsis study as of July 2026, indicating active clinical development efforts [N7].
- Bluejay is preparing to submit a 510(k) regulatory application to the FDA in the first half of 2027 for its Symphony IL-6 diagnostic, aiming for FDA approval thereafter [S2].
- Bluejay Diagnostics strengthened its cash position as reported in Q2 2026 results, with cash and cash equivalents of approximately $7.4 million as of September 30, 2026 [N5][S2].
- The company reported a net loss of approximately $2.0 million for the nine months ended September 30, 2026, and an accumulated deficit of about $47.7 million since inception [S2].
- Bluejay Diagnostics announced a 1-for-4 reverse stock split in November 2026 [N1].
- The company has engaged in strategic partnerships, including with Lovell to access the U.S. federal healthcare market and with Argonaut, reflecting efforts to expand market reach [N4][N9].
- Bluejay Diagnostics' common stock is listed on the Nasdaq Capital Market and must maintain a minimum bid price of $1.00 to remain listed; as of November 11, 2026, the stock price was $2.80 [S2].
- The company faces risks related to capital requirements and liquidity, with a need to raise additional capital to continue operations and implement its business plan [S2].
- Liquidity ratios as of September 30, 2026, include a current ratio of 3.91 and a cash ratio of 3.83, indicating a strong short-term liquidity position [S2].
- Bluejay Diagnostics has conducted private placements to raise capital, including an offering of 2.692 million shares at $1.30 per share in late 2023 [N10].
- The company has experienced multiple reverse stock splits, including a 1-for-50 split in November 2024 and a 1-for-4 split in November 2026, which may reflect efforts to maintain listing compliance [N1][N11].
Generated 2026-11-13
- S1 | 2026-03-06 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-04 | www.nasdaq.com | Bluejay Diagnostics, Inc. Announces 1-for-4 Reverse Stock Split | https://www.nasdaq.com/articles/bluejay-diagnostics-inc-announces-1-4-reverse-stock-split
- N2 | 2026-09-11 | www.nasdaq.com | Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials | https://www.nasdaq.com/articles/weekly-buzz-jnj-wins-fda-nod-axgn-hcwb-strike-deals-roiv-azn-gpcr-lead-clinical-trials
- N3 | 2026-09-08 | www.nasdaq.com | 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara | https://www.nasdaq.com/articles/5-biotech-stocks-watch-bluejay-pharvaris-roivant-pdsb-atara
- N4 | 2026-09-08 | www.nasdaq.com | Bluejay Diagnostics, Lovell Team Up To Access U.S. Federal Healthcare Market | https://www.nasdaq.com/articles/bluejay-diagnostics-lovell-team-access-us-federal-healthcare-market
- N5 | 2026-08-13 | www.nasdaq.com | Bluejay Reports Q2 2026 Results; Cash Position Strengthened Ahead Of Symphony IL-6 FDA Filing | https://www.nasdaq.com/articles/bluejay-reports-q2-2026-results-cash-position-strengthened-ahead-symphony-il-6-fda-filing
- N6 | 2026-08-06 | www.nasdaq.com | Top Biotech Gainers: ATTO Debuts, AMWL Cuts Loss, PRGO Returns To The Black, URGN Hits New High | https://www.nasdaq.com/articles/top-biotech-gainers-atto-debuts-amwl-cuts-loss-prgo-returns-black-urgn-hits-new-high
- N7 | 2026-07-21 | www.nasdaq.com | Bluejay Completes Enrollment In SYMON-II Sepsis Study | https://www.nasdaq.com/articles/bluejay-completes-enrollment-symon-ii-sepsis-study
- N8 | 2026-06-05 | www.nasdaq.com | Weekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN | https://www.nasdaq.com/articles/weekly-buzz-phg-kmda-win-fda-nod-fulc-halts-pociredir-rmd-closes-noctrix-deal-nvs-paces
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


